If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOKYO.L Regulatory News (OKYO)

  • There is currently no data for OKYO

Emerging Metals Increases Stake

23 Feb 2009 16:47

RNS Number : 7522N
Kalahari Minerals PLC
23 February 2009
 



Kalahari Minerals plc / Ticker: KAH / Index: AIM / Sector: Mining & Exploration

23 February 2009

Kalahari Minerals plc ('Kalahari' or 'the Company')

Emerging Metals Increases Stake 

Kalahari Minerals plc, the AIM listed mining exploration group with a portfolio of copper, base metal and uranium interests in Namibia, was notified on 23 February 2009 that Emerging Metals Limited has purchased 2,475,000 ordinary shares in the Company, representing approximately 1.38% of the Company's total voting rights, raising its total interest in Kalahari to 15,820,000 ordinary shares representing 8.84% of its total voting rights.

* * ENDS * *

For further information please visit www.kalahari-minerals.com or contact:

Mark Hohnen

Kalahari Minerals Plc

Tel: +61 (0) 8 9389 4488

Olly Cairns

Blue Oar Securities Plc

Tel: +61 (0) 86430 1631

Romil Patel

Blue Oar Securities Plc

Tel: 020 7448 4400

Richard Chase

Ambrian Partners

Tel: 020 7634 4700

Victoria Thomas

St Brides Media & Finance Ltd

Tel: 020 7236 1177

Hugo de Salis

St Brides Media & Finance Ltd

Tel: 020 7236 1177

Notes to Editors:

Information relating Kalahari

Kalahari Minerals Plc is an AIM listed mining and exploration group with a portfolio of copper and base metal prospects within western and eastern central Namibia. Two of the project areas, Dordabis and Witvlei, are prospective for sediment hosted copper mineralisation consistent with the world class Zambian Copper Belt. A third project, Ubib, is believed to be prospective for gold mineralisation and is located close to the operating Navachab gold mine.

The Company also has a 100% interest in the highly prospective Namib Lead Zinc Project centred on the old Namib Lead Mine, which was an underground operation from 1965 - 1992. Previous mine studies (non JORC compliant) indicate surface tails and underground mining reserves of 1.65 million tonnes at 5.7% zinc, 1.6% lead and 40.2 g/t silver. Kalahari aims to take the project to bankable feasibility study stage with a view to recommencing mining operations in the short term.

Additionally, the Company holds a 40.60% interest in ASX and TSX listed Extract Resources Limited, which is focused on uranium exploration. Its key project is the Husab uranium project in Namibia which contains three main prospects, Rossing South, Ida Dome and Hildenhof, and is located directly south of Rio Tinto's producing Rossing Mine. At Rossing South, an initial resource estimate of 108 M lbs of U3O8 at a grade of 430 ppm was recently announced, whilst at Ida Dome, a 25.1 M lbs of U3O8 has been defined, effectively giving Extract a total resource of 133.1 M lbs. Results from an ongoing drilling programme reinforce the Company's belief that the area has a strong potential to host a world class uranium deposit.

Information relating to Extract

Extract Resources Limited is an Australian-based uranium exploration company whose primary focus is in the African nation of Namibia. Extract's principal asset is its 100%-owned Husab Uranium Project which contains three known uranium targets: Ida Dome; Hildenhof; and Rossing South. Rossing South represents Extract's first new discovery in this area. Extract is listed on the ASX and the TSX under the ticker symbol 'EXT'. For more information on Extract visit www.extractresources.com.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLPUUQCPUPBGQW
Date   Source Headline
7th Sep 20221:30 pmRNSResult of AGM
30th Aug 20227:00 amRNSQ4 '22 IND planned followed by P2 with AmbioPharm
19th Aug 20227:00 amRNSNotice of AGM
18th Aug 20222:06 pmRNSSecond Price Monitoring Extn
18th Aug 20222:00 pmRNSPrice Monitoring Extension
16th Aug 20227:00 amRNSAnnual Financial Report
9th Jun 20227:08 amRNSDirector/PDMR Shareholding
20th May 20227:00 amRNSDirector/PDMR Shareholding
19th May 20224:01 pmRNSClosing of Offering
18th May 202210:10 amRNSDirector/PDMR Shareholding
17th May 20227:00 amRNSOKYO Announces Pricing of IPO of ADSs in the U.S.
27th Apr 20227:00 amRNSUpcoming Presentations at Ophthalmic Conference
7th Mar 20227:00 amRNSAdditional Listing
23rd Feb 20227:00 amRNSPatent issued: to treat ocular neuropathic pain
21st Feb 20225:00 pmRNSCLN Conversion, exercise of Warrants, equity issue
15th Feb 20227:00 amRNSSuccessful Pre-IND Meeting with the FDA on OK-101
1st Feb 20227:00 amRNSDirector/PDMR Shareholding
27th Jan 20227:00 amRNSDirector/PDMR Shareholding
26th Jan 20222:05 pmRNSSecond Price Monitoring Extn
26th Jan 20222:00 pmRNSPrice Monitoring Extension
26th Jan 20227:00 amRNSHalf-year Report
14th Dec 20217:00 amRNSU.S. Patent issued for use of OK-101 to treat DED
13th Dec 20217:00 amRNSOK-101:Anti-inflammatory & Pain-Reducing Potential
6th Dec 20217:00 amRNSIND filing Q3 2022 and Phase 2 initiation Q4 2022
1st Dec 20217:00 amRNSDirectorate Change
19th Oct 20214:41 pmRNSSecond Price Monitoring Extn
19th Oct 20214:35 pmRNSPrice Monitoring Extension
19th Oct 20212:05 pmRNSSecond Price Monitoring Extn
19th Oct 20212:00 pmRNSPrice Monitoring Extension
27th Sep 202112:06 pmRNSResult of AGM
9th Sep 20217:00 amRNSNotice of AGM
1st Sep 20217:00 amRNSDirector/PDMR Shareholding
2nd Aug 202111:32 amRNSAnnual Financial Report
29th Jun 20217:00 amRNSResearch Update
17th Jun 20213:58 pmRNSDirectorate Change
12th May 20217:00 amRNSHolding(s) in Company
7th May 202110:07 amRNSAdditional Listing
5th May 202111:53 amRNSPublication of a Prospectus
28th Apr 20217:00 amRNSPositive Data in an Animal Model using OK-201
29th Mar 20217:00 amRNSAppointment of Chief Scientific Officer
3rd Mar 20217:00 amRNSIssue of Equity
1st Mar 20217:00 amRNSIssue of Equity
23rd Feb 20217:00 amRNSPatent for treating Ocular Pain and Inflammation
19th Jan 20217:00 amRNSFiling patent application for the use of Chemerin
14th Jan 20214:41 pmRNSSecond Price Monitoring Extn
14th Jan 20214:37 pmRNSPrice Monitoring Extension
14th Jan 20212:05 pmRNSSecond Price Monitoring Extn
14th Jan 20212:00 pmRNSPrice Monitoring Extension
7th Jan 20217:00 amRNSDirectorate Change
30th Nov 20207:00 amRNSHalf-year Report

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.